Why the study?
Does P2Y12 genetic polymorphism testing predict clopidogrel resistance in Indonesian stroke patients?
Does P2Y12 genetic polymorphism testing predict clopidogrel resistance in Indonesian stroke patients?
Routine P2Y12 genetic testing may not yield significant clinical utility in Indonesian stroke patients due to the low baseline prevalence of resistance-associated mutations.
Answers are grounded in this paper and cite their sources.
May limit routine P2Y12 testing utility in Indonesian stroke patients; leaves open its predictive value for clopidogrel resistance.
Indonesia showed a low clopidogrel resistance rate and a very low C34T and G52T allele P2Y12 gene mutation, meaning that Indonesia had low mutations in the P2Y12. This is the cause of clopidogrel resistance in this study only 15%. Therefore, in a region with less clopidogrel resistance, examination of the P2Y12 gene would not give significant results.
No takes yet. Share an insight, caveat, or question.
Hidayat et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: